You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

CLINICAL TRIALS PROFILE FOR FLOXURIDINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Floxuridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001576 ↗ A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver Completed National Cancer Institute (NCI) Phase 1 1997-07-01 Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan. Postoperatively, patients will be treated with hepatic arterial infusion of floxuridine (FUDR), 0.2 mg/kg/day and leucovorin (LV), 15 mg/M2/day as a 2-week continuous infusion regimen. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed.
NCT00002716 ↗ Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Completed National Cancer Institute (NCI) Phase 3 1996-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver metastases from colorectal cancer.
NCT00002716 ↗ Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Completed Alliance for Clinical Trials in Oncology Phase 3 1996-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver metastases from colorectal cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Floxuridine

Condition Name

Condition Name for Floxuridine
Intervention Trials
Colorectal Cancer 18
Metastatic Cancer 11
Liver Metastases 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Floxuridine
Intervention Trials
Colorectal Neoplasms 28
Neoplasm Metastasis 25
Liver Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Floxuridine

Trials by Country

Trials by Country for Floxuridine
Location Trials
United States 92
China 5
Canada 2
Switzerland 1
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Floxuridine
Location Trials
New York 19
Maryland 7
New Jersey 6
California 6
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Floxuridine

Clinical Trial Phase

Clinical Trial Phase for Floxuridine
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 1
Phase 2 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Floxuridine
Clinical Trial Phase Trials
Completed 27
Recruiting 10
Active, not recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Floxuridine

Sponsor Name

Sponsor Name for Floxuridine
Sponsor Trials
National Cancer Institute (NCI) 23
Memorial Sloan Kettering Cancer Center 14
NYU Langone Health 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Floxuridine
Sponsor Trials
Other 68
NIH 25
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.